Related Experiment Video
Updated: Aug 23, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Treating the Patient with Kidney Failure to Reduce Cardiovascular Disease Risk
Vandana Menon1, Mark J. Sarnak
1Division of Nephrology, Tufts-New England Medical Center, 750 Washington Street, NEMC #391, Boston, MA 02111, USA. msarnak@tufts-nemc.org
Insights
Managing cardiovascular disease risk in kidney failure requires addressing modifiable factors and implementing proven treatments. Key interventions include blood pressure control, dyslipidemia management with statins, and anemia treatment with iron and erythropoietic agents.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular disease (CVD) is a major cause of mortality in patients with kidney failure.
- Effective management of CVD risk factors is crucial for improving patient outcomes.
Purpose of the Study:
- To outline evidence-based strategies for reducing cardiovascular disease risk in patients with kidney failure.
- To provide guidance on managing key modifiable risk factors and implementing proven interventions.
Main Methods:
- Review of current guidelines and clinical evidence for CVD risk reduction in kidney failure.
- Focus on management of blood pressure, dyslipidemia, anemia, mineral and bone disorders, and specific cardiovascular conditions.
Main Results:
- Volume status management is critical for blood pressure control.
- Statins are recommended for dyslipidemia; intravenous iron and erythropoietic agents for anemia.
- Specific pharmacotherapies and interventions are recommended for ischemic heart disease and heart failure with reduced ejection fraction.
- Coronary artery bypass graft surgery may offer survival benefits over percutaneous coronary interventions in select patients.
Conclusions:
- Comprehensive management of modifiable risk factors is essential for reducing cardiovascular risk in kidney failure.
- Targeted interventions for anemia, mineral and bone disorders, and specific cardiac conditions improve patient prognosis.
- Surgical revascularization strategies should be carefully considered for patients requiring coronary intervention.
Abstract:
The reduction of cardiovascular disease risk in kidney failure involves treatment of modifiable risk factors and provision of proven interventions to patients with established disease. Volume status management is key to blood pressure control. Statins are the agents of choice for the treatment of dyslipidemia. Target hemoglobin levels should be achieved using intravenous iron and erythropoietic agents. Combinations of calcium and noncalcium-containing phosphorus binders and vitamin D and its analogues should be used to attain target parathyroid hormone, phosphorus, and calcium phosphorus product levels. beta Blockers and aspirin are recommended in patients with ischemic heart disease and angiotensin-converting enzyme inhibitors (or angiotensin II receptor blockers), and beta blockers are recommended in patients with heart failure with reduced ejection fraction. In patients who require revascularization, studies suggest a survival benefit of coronary artery bypass graft surgery over percutaneous transluminal coronary angioplasty and coronary artery stenting.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease IV: Nursing Management
